Pericarditis is a small but fast-evolving therapeutic area in the US, with unmet need concentrated in recurrent patients. FDA approval of an IL-1 inhibitor has reshaped treatment expectations and encouraged further R&D investment. Cardiologists are increasingly considering biologics earlier for steroid-dependent patients. Cost and payer prior authorization remain barriers to wider...